NCIt definition : A glycoengineered, humanized monoclonal antibody directed against the fibroblast growth
factor receptor type 2b (FGFR2b), with potential antineoplastic activity. Upon administration,
bemarituzumab specifically binds to and inhibits FGFR2b on tumor cell surfaces, which
prevents FGFR2 from binding to its ligands, FGFR2b activation and the activation of
FGFR2b-mediated signal transduction pathways. The binding of FPA144 to FGFR2b protein
also induces antibody-dependent cell-mediated cytotoxicity (ADCC) against FGFR2b-expressing
tumor cells. This results in the inhibition of cell proliferation and the induction
of cell death of FGFR2-expressing tumor cells. FGFR2b, a specific isoform of the receptor
tyrosine kinase FGFR2 upregulated in many tumor cell types, is essential to tumor
proliferation, differentiation and survival. Glycoengineering enhances the FPA144-mediated
ADCC.;
UNII : RJW23BQ0KW;
CAS number : 1952272-74-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1952272-74-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;